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Recent studies have demonstrated that embryonic stem cell-
like induced pluripotent stem (iPS) cells can be generated by
enforced expression of defined transcription factors. The fact
that cell fate change is accompanied by changes in epigenetic
modifications prompted us to investigate whether chemicals
known tomodulate epigenetic regulators are capable of enhanc-
ing the efficiency of iPS cell generation. Here, we report that
butyrate, a natural small fatty acid and histone deacetylase inhibi-
tor, significantly increases the efficiency of mouse iPS cell genera-
tion using the transcription factors Oct4, Sox2, Klf4, and c-Myc.
We show that butyrate not only changes the reprogramming
dynamics, but also increases the ratio of iPS cell colonies to total
coloniesby reducing the frequencyofpartially reprogrammedcells
and transformed cells. Detailed analysis reveals that the effect of
butyrate on reprogramming appears to bemediated by c-Myc and
occurs during an early stage of reprogramming. Genome-wide
gene expression analysis reveals up-regulation of ES cell-enriched
geneswhenmouse embryonic fibroblasts are treatedwith butyrate
during reprogramming. Thus, our study identifies butyrate as a
chemical factor capable of promoting iPS cell generation.
Reprogramming from somatic cells to induced pluripotent
stem (iPS)2 cells can be achieved by retroviral expression of
transcription factors Oct4, Sox2, Klf4, and c-Myc (1–4). How-
ever, the slow reprogramming process and low reprogramming
efficiency impede detailed mechanistic studies and potential
applications of this technology.One solution to overcome these
problems is to identify small molecules that can enhance the
reprogramming efficiency. Indeed, recent studies have demon-
strated that several chemicals with the capacity to modulate
epigenetic enzymes exhibit positive effects on iPS cell genera-
tion. For example, valproic acid (VPA), a histone deacetylase
inhibitor, has been shown to improve both the kinetics and
efficiency of mouse and human iPS cell generation (5, 6). In
addition, BIX-01294, an inhibitor for the histone methyltrans-
ferase G9a, and RG108, a DNA methyltransferase inhibitor,
have been reported to enhance the efficiency of iPS cell gener-
ation (7, 8). Furthermore, another DNA methyltransferase
inhibitor, 5-aza-cytidine, has been shown to facilitate the con-
version of partially reprogrammed cells to fully reprogrammed
iPS cells (9).
Recently, butyrate, a naturally occurring short chain fatty
acid and histone deacetylase inhibitor, has been shown to sup-
port self-renewal of both human and mouse embryonic stem
(ES) cells in a range of relatively low concentrations (10). How-
ever, butyrate has also been reported to induce differentiation
when applied at higher concentrations (11). Therefore, whether
butyrate has an effect on iPS cell generation is an intriguing
question. In this report, we sought to examine the effect of
butyrate on iPS cell generation. We found that butyrate facili-
tates iPS cell generation in the range of 0.5–1 mM. This effect
appears to bemediated through one of the reprogramming fac-
tors c-Myc. In addition, butyrate is able to increase the percent-
age of fully reprogrammed iPS cells by reducing partially and/or
unsuccessfully reprogrammed cells. Genome-wide gene
expression analysis indicates that butyrate can specifically
increase the expression of some ES cell-enriched genes in fibro-
blasts in the presence of exogenous c-Myc. Thus, our studies
uncover another chemical capable of facilitating iPS cell gener-
ation, contributing to the iPS cell tool box.
EXPERIMENTAL PROCEDURES
Mouse Embryonic Fibroblast (MEF) Derivation and iPS Cell
Culture—MEFs were derived from day 13.5 embryos (E13.5) of
Sox2-GFP/Rosa26-M2rtTA double knock-in mice. MEFs were
cultured in rich fibroblast growth medium (Dulbecco’s modified
Eagle’s medium supplemented with 15% fetal bovine serum, non-
essential amino acid, GlutaMax, and penicillin/streptomycin) for
nomore than twopassagesbefore retroviral transduction. iPScells
were cultured in mouse ES cell medium (Dulbecco’s modified
Eagle’s mediumwith 15% fetal bovine serum, nonessential amino
acid, GlutaMax, sodium pyruvate, -mercaptoethanol, penicillin/
streptomycin, and 1,000 units/ml leukemia inhibitory factors)
with mitomycin C-treated STO cells as feeder cells or on 0.1%
gelatin-coated plates.
Retrovirus Preparation and Infection—Retroviral plasmids
pMXs expressing murine Oct4, Sox2, Klf4, and c-Myc (2) were
transfected respectively into 293T cells with packaging plas-
mids pGag-pol and pVSVG. Virus-containing supernatants
were harvested at 48 and 72 h after transfection, filtered
through 0.45-m filter membrane, and concentrated by spin
column before being used inMEF transduction in the presence
of Polybrene (5 g/ml).
Generation of iPS Cells and Calculation of Reprogramming
Efficiency—MEFs were seeded in 6-well plates with 1  105
cells/well, 16 h before the first infection. Concentrated viruses
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were applied toMEFs twice within 48 h. The day when the viral
supernatant was removed was defined as day 0 after infection.
Transduced fibroblasts were then cultured in mouse ES cell
medium in the presence or absence of butyrate for 12–16 days.
The concentration of butyrate used was 1 mM, except stated
otherwise. In most cases, reprogramming efficiency is repre-
sented by the Sox2-GFP colony number derived from 1  105
MEFs; in some case, relative reprogramming efficiency is also
used, which is the fold change of Sox2-GFP colony number
with butyrate treatment compared with that without treat-
ment. Alkaline phosphatase (AP) staining was performed with
alkaline phosphatase detection kit (Millipore).
Teratoma Formation and Analysis—Teratomas were in-
duced by subcutaneously injecting 1  106 iPS cells into
Rag2/::C/ immunodeficient mice. Xenografted tumor
samples were isolated from mice in 4–6 weeks, fixed by 4%
paraformaldehyde, embedded in paraffin, and processed for
hematoxyin and eosin staining, using standard protocols.
Quantitative and Semiquantita-
tive RT-PCR—Total RNAs were
harvested using RNeasy kit (Qia-
gen). Primers for quantitative and
semiquantitative RT-PCR are listed
in supplemental Table 1. Quantita-
tive PCRs were performed with
SYBR GreenER mix (Invitrogen).
Relative gene expression levels were
normalized to GapdhmRNA.
Genome-wide Expression Anal-
ysis—2g of total RNAwas reverse-
transcribed into cDNA with a
T7-(dT)24 primer from a custom
kit (Invitrogen). Biotinylated cRNA
was then generated from the cDNA
reaction using the BioArray High
Yield RNA Transcript kit. The
cRNA was then fragmented in frag-
mentation buffer (40 mM Tris ace-
tate, pH 8.1, 100mMKOAc, and 150
mM MgOAc) at 94 °C for 35 min
before microarray hybridization. 15
g of fragmented cRNA was then
added to a hybridization mixture
(0.05 g/l fragmented cRNA, 50 pM
control oligonucleotide B2, BioB,
BioC, BioD, and Cre hybridization
controls, 0.1 mg/ml herring sperm
DNA, 0.5 mg/ml acetylated bovine
serum albumin, 100 mM MES, 1 M
[Na], 20 mM EDTA, 0.01% Tween
20). 10 g of cRNA was used
for hybridization to Affymetrix
GeneChip Mouse Genome 430A
2.0 Array. Hybridization was car-
ried out at 45 °C for 16 h. The array
was then washed and stained with
R-phycoerythrin streptavidin before
scanning. Washing, scanning, and
basic analysis were carried out using Affymetrix GeneChip
Microarray Suite 5.0 software. For details ofWestern blotting, see
supplemental Methods.
RESULTS
Butyrate Promotes iPS Cell Generation—A recent study indi-
cated that butyrate, a small fatty acid, supports self-renewal in
mouse and human embryonic stem cells (10). To determine
whether butyrate has an effect on iPS cell generation, we trans-
duced 1  105 MEFs derived from hemizygote a Sox2-GFP
mouse with retroviruses expressing Oct4, Sox2, Klf4, and
c-Myc in the presence of varying concentrations of butyrate.
The effect of butyrate on reprogramming was monitored for a
period of 12 days after infection. In the presence of butyrate,
GFP colonies with ES cell-like morphology were observed at
day 6 after infection (Fig. 1A). At day 8, we observed a dose-de-
pendent enhancement of reprogramming efficiency when
butyrate was used at concentrations between 0.25 and 1 mM. A
FIGURE 1. Butyrate promotes iPS cell generation. A, representative Sox2-GFP iPS cell colony generated in
the presence of butyrate at postinfection day 6. Scale bar, 100 m. MEFs from hemizygote Sox2-GFP mouse
were transduced with Oct4, Sox2, Klf4, and c-Myc (4F) and treated with butyrate. B, GFP colony numbers
counted at posttransduction day 8 (left panel) of 1  105 MEFs with the four reprogramming factors in the
absence or the presence of various concentrations (0.25, 0.5, 1, 1.5, and 2 mM) of butyrate or VPA (1 mM).
Presented in the right panel are the numbers of GFP and total colony counted at day 12 after transduction.
Subsequently, cells were stained for AP. The number of GFP colonies (green), APGFP colonies (purple), and
APGFP colonies (gray) are shown in the chart. C, representative fluorescent microscopic pictures taken at
day 12 after transduction by 4F and 4F in the presence of 0.5 mM butyrate (4FB). Arrows indicate Sox2-GFP
colonies. Scale bar, 1 mm.
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maximum 7-fold increase was observed when butyrate was
applied at 1 mM. However, at higher concentrations (1.5 and 2
mM), butyrate becomes cell-toxic, and no GFP colonies were
observed (Fig. 1B). On day 12, treatment of butyrate at 0.5 and
1 mM still showed an approximate 2-fold increase in the num-
ber of GFP colonies (Fig. 1B, right panel, green bars). The
effect of butyrate on promoting the generation of GFP iPS cell
colonies is comparable with that of VPA (Fig. 1B).
In addition to counting the GFP iPS cell colony numbers,
we also counted the total and the AP-positive colony numbers
on day 12. Interestingly, at lower concentrations of butyrate
(0.25–1 mM), both the AP and total colony numbers show
a concentration-dependent reduction (Fig. 1B, right panel),
although more GFP colonies were observed. This leads to
exceptionally high GFP/AP and GFP/total colony ratios
under butyrate treatment, which is distinct from the effect of
VPA (Fig. 1B, right panel). For example, in the absence of buty-
rate, only 20% of the total colonies are GFP and 63% are AP; at
0.5 mM, 66% are GFP and 83% are AP; at 1 mM, these ratios
are further increased to 92 and 96%, respectively (Fig. 1B, right
panel, and Fig. 1C). Because Sox2-GFP is a more stringent plu-
ripotency marker than AP, the reduction of GFP colonies in
total population and AP population suggests that butyrate is
capable of suppressing the formation of transformed cells or
partially reprogrammed cells that were not destined to the plu-
ripotent cell fate. This observation is consistent with the well
characterized effect of butyrate on limiting the cell growth of
cancerous cells (12).
Butyrate Accelerates iPS Cell Generation, and Its Effect Is
c-Myc-dependent—To characterize further the effect of buty-
rate on iPS cell generation, wemonitored the effect of butyrate (1
mM) on the kinetics of reprogramming by introducing the four
transcription factors (4F; Oct4, Sox2, Klf4, and c-Myc) and
three factors (3F; Oct4, Sox2, and Klf4). In the case of 4F repro-
gramming, butyrate accelerated formation of GFP colonies by
2–3 days until postinfection day 16 when the effect of butyrate
on the GFP colony number becomes unnoticeable (Fig. 2A).
However, when the reprogramming
was performed using three factors,
butyrate appears to have a negative
effect on reprogramming efficiency
(Fig. 2A). This suggests that the
enhancement effect of butyrate on
reprogramming is dependent on
exogenous c-Myc under our exper-
imental condition. We also moni-
tored the number of AP colony
and total colony at postinfection day
12. In both 4F and 3F reprogram-
ming, butyrate strongly reduces the
total colony number and GFP col-
ony number (Fig. 2B), indicating
that butyrate is capable of limiting
the formation of partially repro-
grammed cells or transformed cells
regardless of whether three factors
or four factors were used for repro-
gramming. In addition, we also
tested the potential effect of butyrate on reprogramming by
withdrawing other factors from the 4F combination; however,
we did not observe any positive effect of butyrate on repro-
gramming under these conditions (data not shown).
Sox2-GFP-positive Colonies Are Pluripotent—Next, we set
out to characterize the GFP colonies generated in the pres-
ence of butyrate. To this end, individual GFP colonies were
picked up and propagated in standard ES cell culture medium
in the absence of butyrate. All of the GFP colonies derived in
the presence of butyrate exhibit ES-like morphology (Fig. 3A)
and high AP activity (Fig. 3B). We randomly picked three colo-
nies for further characterization. RT-PCR analysis demon-
strated that all three lines expressed endogenous genes encod-
ing stem cell factors Oct4, Sox2, Nanog, as well as other
pluripotency-related genes, such as Fbxl15 and Utf1 (Fig. 3C).
When these iPS cells were injected into immunodeficientmice,
all lines were able to form complex-structured teratoma con-
taining tissues from the three germ layers (Fig. 3D). Collec-
tively, these results suggest that Sox2-GFP cells generated in
the presence of butyrate are pluripotent.
Butyrate Facilitates iPS Cell Generation in an Early Time
Window—To shed light on the role of butyrate in promoting
iPS generation, we sought to determine the time window dur-
ing which butyrate exerts its effect. First, butyrate was applied
to the culture medium immediately after infection and was
withdrawn from themediumat different time points during the
12-day reprogramming process (Fig. 4A, left panel). Success-
fully reprogrammedGFP colonieswere counted at day 12, and
the effect of butyrate on reprogramming was determined by
comparison with GFP colony numbers in the absence of
butyrate. Results shown in Fig. 4A (right panel) demonstrate
that the exposure to butyrate for only 2–4 days following trans-
duction has an effect similar to that of continued exposure dur-
ing the reprogramming process. Next, we determined whether
the 2–4 days of butyrate treatment needed to be performed at a
particular time point during the reprogramming process. To
this end, butyrate was added to the culture medium at different
FIGURE 2. Butyrate improves the reprogramming kinetics in a c-Myc-dependent manner. A, kinetics of
reprogramming in the presence of butyrate. Sox2-GFP MEFs transduced with 4F and 3F were treated with
butyrate (1 mM). The number of GFP colonies for each treatment was counted at different days until day 16
after transduction. B, GFP colonies and total colonies at day 12. AP colonies were also counted, after cells
were stained for AP.
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time points during the reprogram-
ming process (Fig. 4B, left panel),
and the effect of butyrate on repro-
gramming was determined in a way
similar to that described above.
Interestingly, we found that expo-
sure to butyrate from day 2 after
transduction has the maximum
positive effect on the efficiency of
reprogramming. Based on the above
experiments, we conclude that
butyrate exhibits the maximum
effect on iPS generation at the initial
2–4 days of reprogramming, sug-
gesting that butyrate functions early
during the reprogramming process.
Our findings that butyrate exerts its
effect in a c-Myc-dependent man-
ner (Fig. 2) and that this occurs early
during the reprogramming process
are consistent with previous studies
demonstrating that Myc mainly
contributes to reprogramming at an
early stage (13).
Butyrate Up-regulates a Set of
ES Cell-enriched Genes in c-Myc-
mediated Reprogramming—To gain
insight into the molecular mecha-
nism of butyrate enhanced repro-
gramming, we carried out gene
expression studies using cDNA
microarrays with the following four
samples: (i) 4F transduction, (ii) 4F
transduction with butyrate treat-
ment (4FB), (iii) 3F transduction,
and (iv) 3F transduction with buty-
rate treatment (3FB). Because the
effective time window for butyrate
is 2–4 days after infection and
because we are mainly interested in
a primary effect, we treated the
transduced MEFs with butyrate for
a period of 48 h prior to harvesting
RNA. We first focused on the genes
whose expression is at least 8-fold
higher in ES cells than in MEFs (9).
We plotted the expression level of
these ES cell-enriched genes in 4F
(Fig. 5A, red dots) and 3F (blue
dots)-transducedMEFs at day 2 on a
scatter chart, in which the x and y
axis, respectively, represent the
expression level in the absence or
presence of butyrate (Fig. 5A). Lin-
ear regression of the scatter plot
shows that the slope of the 4F
regression line (1.3137) is signifi-
cantly higher than that of the 3F
FIGURE 3. iPS cells generated in the presence of butyrate are pluripotent. A, representative pictures of
an iPS cell line derived in the presence of butyrate. iPS cell lines derived from 4F reprogramming in the
presence of butyrate were cultured in ES cell medium on gelatin-coated plates without feeder cells. Scale
bar, 100 m. B, AP activity of an iPS cell line derived in the presence of butyrate. Scale bar, 100 m.
C, RT-PCR demonstrating that three randomly picked iPS cell lines derived in the presence of butyrate
express pluripotent marker genes. D, representative pictures of teratoma derived from butyrate-assisted
iPS cell lines comprising cell types from all three germ layers (endoderm, mesoderm, and ectoderm). Scale
bar, 100 m. All three randomly picked iPS cell lines showed a similar capacity in generating teratomas
harboring cells belonging to the three germ layers.
FIGURE 4. Butyrate facilitates iPS cell generation at an early time window during reprogramming.
A, Sox2-GFP MEFs transduced with 4F were treated with butyrate immediately after transduction with 4F,
and butyrate was removed from the culture medium at different time points. GFP colonies were counted
at day 12. The reprogramming efficiencies of various treatments were compared with that without the
butyrate treatment and are presented in the right panel. B, Sox2-GFP MEFs transduced with 4F were
treated with butyrate at different times after transduction with 4F, and butyrate was maintained in the
culture media until day 12 when the GFP colonies were counted. The reprogramming efficiencies of
various treatments were compared with that without the butyrate treatment and are presented in the
right panel.
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regression line (1.0918), indicating that the expression of these
ES cell-enriched genes as a whole is increased by butyrate treat-
ment in a c-Myc-dependent manner (Fig. 5A). Similarly, we
have also analyzed the expression of MEF-enriched genes in
response to butyrate treatment in reprogramming. However, a
significant down-regulation of these genes due to the treatment
of butyrate was not noticed, regardless of whether 4F or 3F was
used in reprogramming (data not shown).
Further analysis of the microarray data indicates that a total
of 337 probes were at least 2-fold up-regulated by the treatment
of butyrate in the 4F reprogramming, whereas only 182 probes
were up-regulated at least 2-fold in 3F reprogramming (Fig. 5B).
Interestingly, 199 of the 337 probes up-regulated in the 4F
reprogramming appear to be c-Myc-dependent as butyrate
treatment failed to significantly up-regulate them in the 3F
reprogramming. Among the 199 probes, 21 probes correspond
to 19 known ES cell-enriched genes (supplemental Table 2).
RT-quantitative PCR analysis of randomly selected genes out of
the 19 ES cell-enriched genes confirmed that their expression is
significantly up-regulated by the treatment of butyrate in the 4F
reprogramming, but not in the 3F reprogramming (Fig. 5C).
The selected genes, Bex1,Mreg, and Krt12 are most up-regulated
by butyrate at the concentration of 1 mM (supplemental Fig. 1),
which is consistent with the ob-
served maximum effect of butyrate
on iPS cell generation at this con-
centration. How up-regulation of
these genes contributes to the iPS
cell generation process remains to
be determined.
DISCUSSION
In this study, we demonstrate
that butyrate, a small fatty acid and
histone deacetylase inhibitor, pro-
motes mouse iPS cell generation by
Oct4, Sox2, Klf4, and c-Myc. Under
the optimal concentration (0.5–1
mM), butyrate can enhance the gen-
eration of Sox2-GFP iPS cells by
7-fold when the four factors were
used in reprogramming (Fig. 1B).
Butyrate facilitates iPS cell genera-
tionmainly by shifting the kinetic of
4F reprogramming 2–3 days for-
ward (Fig. 2A). A recent study indi-
cated that ES cell self-renewal is
facilitated by the presence of butyrate
at a lower concentration (around
0.2 mM) (10). Given that butyrate
can relax the chromatin structure
by functioning as a histone deacety-
lase inhibitor, a higher (0.5–1 mM)
optimal concentration in 4F re-
programming might indicate that
establishment of pluripotency may
need more accessible chromatin
structure compared with that re-
quired for maintenance of ES cell status. Although butyrate is
widely used as a differentiation reagentwhen applied at a higher
concentration (1 mM) (11), we did not notice differentiation
of the fully reprogrammedSox2-GFP colonies during the time
of butyrate treatment. Neither did we observe any negative
effect of butyrate on the quality of iPS cells derived in the pres-
ence of butyrate. The apparent conflicting roles that butyrate
displays in differentiation and iPS cell generation suggest that
this epigenetic modulator may generally facilitate cell fate
changes by increasing the flexibility of chromatin. In this
regard, it will be interesting to test whether butyrate can facili-
tate transdifferentiation between different cell types, for exam-
ple from fibroblasts to muscle cells (14) and from B cells to
macrophage (15).
In addition to facilitating iPS cell generation, we also noticed
that butyrate can reduce the GFP colony numbers, regardless
of their AP activity status. This effect results in a significant
increase in the ratio of GFP colonies, representing authenti-
cally reprogrammed iPS cells (Fig. 1, B and C). The APGFP
colonies are probably cells that failed to express all four repro-
gramming factors. These cells usually exhibit properties of
transformed cells, such as granulated or cobblestone morphol-
ogy with fast cell growth (2). Elimination of these APGFP
FIGURE 5. Butyrate enhances the expression of a set of ES cell-enriched genes in a c-Myc-dependent
manner. A, global gene expression was analyzed by microarray (Affymetrix) using total RNA samples har-
vested 2 days after mock or butyrate treatment. The expression levels of ES cell-enriched genes from samples
with butyrate treatment (y axis) are plotted against those without butyrate treatment (x axis). The expression
from cells transduced with 4F and 3F are, respectively, shown in red squares and blue diamonds. The linear
regression line for 4F (red, y  1.3137x  10.675, R2  0.8705) is significantly different (p  0.05) from that of 3F
(blue, y  1.0918x  2.5027, R2  0.9653). B, Venn diagram depicts probes of genes that have 2-fold up-regu-
lation in response to butyrate treatment in 4F (B-up’ed, 4F) or 3F (B-up’ed, 3F) reprogramming. 199 probes that
are up-regulated by butyrate in 4F, but not 3F, reprogramming were further analyzed. C, RT-quantitative PCR
verification of three randomly picked ES cell-enriched genes listed in supplemental Table 2, Mreg, Krt12, and
Bex1, is shown. Data presented are normalized to Gapdh.
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colonies can be attributed to the well characterized anti-cancer
effect of butyrate (12), including induction of p21 and Arf
(supplemental Fig. 2). On the other hand, APGFP colonies
most likely represent partially reprogrammed cells that some-
how have not achieved the pluripotent cell fate (9, 13).With the
assistance of butyrate, these partially reprogrammed cells may
gain full pluripotency and express Sox2-GFP contributing to
the observed higher reprogramming efficiency. We note that
although VPA, another histone deacetylase inhibitor, can also
increase the GFP colony number, it does not seem to have the
same capacity to suppress the total colony numbers (Fig. 1B).
Another epigenetic modulator, 5-aza-cytidine, has been shown
capable of facilitating conversion of partially reprogrammed
cells to fully reprogrammed cells (9). It will be interesting to test
whether butyrate has a similar property. Given that butyrate
functions at an early stage of reprogramming, whereas 5-aza-
cytidine facilitates conversion of partially reprogrammed cells
to fully reprogrammed cells, it will be interesting to test
whether they can function synergistically to facilitate the repro-
gramming process.
Because reprogramming is a process with multiple steps (16,
17), we determined the functioning time window of butyrate to
be at an early stage of the reprogramming process (Fig. 4). This
is consistent with our finding that butyrate facilitates repro-
gramming only in the presence of exogenous c-Myc (Fig. 2) as
c-Myc has been suggested to contribute to the early events of
reprogramming (13). To explore the effect of butyrate in the
early reprogramming process at the molecular level, we ana-
lyzed the genome-wide expression profiles of cells undergoing
reprogramming in this time window. We observed a trend of
up-regulation for ES cell-enriched genes in response to buty-
rate (Fig. 5A), but did not detect genome-wide down-regulation
of MEF-enriched genes (data not shown). This observation is
consistent with the role of butyrate in gene activation as a his-
tone deacetylase inhibitor. Furthermore, we identified 19 ES
cell-enriched genes that are specifically up-regulated by buty-
rate only when c-Myc is included as a reprogramming factor
(supplemental Table 2). It remains to be determined whether
up-regulation of these genes mediates the effect of butyrate.
Given that reprogramming efficiency can be increased by sup-
pression of the p53-p21 pathway (18–21) as well as elimination
of the senescence barrier imposed by Ink4a and/or Arf (22, 23),
we also analyzed whether butyrate can suppress the expression
of p53, p21, Ink4a, and Arf. Instead of down-regulation, we
indeed observed a slight up-regulation of some of these genes
(p21 and Arf) by the butyrate treatment (supplemental Fig. 2),
largely excluding the involvement of p53-p21 pathway and Arf
in mediating the butyrate effects.
During the preparation of this paper,Mali et al. (24) reported
that butyrate greatly facilitates human iPS cell generation. In
their report, reprogramming efficiency is increased remarkably
by butyrate even in the absence of c-Myc and Klf4. Another
difference between these two studies is the timing at which
butyrate exhibits its effect. Although it exerts an effect at an
early stage during reprogramming in mouse cell reprogram-
ming, Mali et al. reported a later effect in human cells (24).
Furthermore, although we noticed an inhibitory effect for
transformed cells and partially reprogrammed cells, it is not
clear whether a similar effect was seen in human cells.Whether
these differences are due to the endogenous c-Myc levels, the
different durations required to achieve reprogramming for
human andmouseMEFs, or other technical aspects remains to
be determined. Nonetheless, the demonstration that butyrate,
an histone deacetylase inhibitor, is capable of facilitating iPS
cell generation suggests that alteration of epigenetic status is an
important step for the establishment of pluripotency.
Acknowledgments—We thank Larysa Pevny for the Sox2-GFP trans-
genic mice, Jin He for technical help, and Anh Tram Nguyen for crit-
ical reading of the manuscript.
REFERENCES
1. Maherali, N., Sridharan, R., Xie,W., Utikal, J., Eminli, S., Arnold, K., Stadt-
feld, M., Yachechko, R., Tchieu, J., Jaenisch, R., Plath, K., and Hoche-
dlinger, K. (2007) Cell Stem Cell 1, 55–70
2. Takahashi, K., and Yamanaka, S. (2006) Cell 126, 663–676
3. Okita, K., Ichisaka, T., and Yamanaka, S. (2007) Nature 448, 313–317
4. Wernig, M., Meissner, A., Foreman, R., Brambrink, T., Ku, M., Hoche-
dlinger, K., Bernstein, B. E., and Jaenisch, R. (2007) Nature 448, 318–324
5. Huangfu, D., Osafune, K., Maehr, R., Guo,W., Eijkelenboom, A., Chen, S.,
Muhlestein,W., andMelton, D. A. (2008)Nat. Biotechnol. 26, 1269–1275
6. Huangfu, D., Maehr, R., Guo, W., Eijkelenboom, A., Snitow, M., Chen,
A. E., and Melton, D. A. (2008) Nat. Biotechnol. 26, 795–797
7. Shi, Y., Desponts, C., Do, J. T., Hahm, H. S., Schöler, H. R., and Ding, S.
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